EN
首页 资讯 期刊 导师 问答 求职 发Paper 文献直达 高级搜索 期刊列表
当前位置： X-MOL 学术 › Cardiovasc. Diabetol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Correction: Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study
Cardiovascular Diabetology ( IF 9.3 ) Pub Date : 2024-03-18 , DOI: 10.1186/s12933-024-02190-6
Phyo T. Htoo , Helen Tesfaye , Sebastian Schneeweiss , Deborah J. Wexler , Brendan M. Everett , Robert J. Glynn , Niklas Schmedt , Lisette Koeneman , Anouk Déruaz-Luyet , Julie M. Paik , Elisabetta Patorno

Correction: Cardiovascular Diabetology (2024) 23:57 https://doi.org/10.1186/s12933-024-02150-0

Following publication of the original article [1], the authors noticed an error in the hazard ratio (HR) for the hospitalization for heart failure (HHF) outcome in the abstract. The numbers in the other parts of the manuscript and the tables were correct.

In abstract section, the correct sentence should read “Compared with GLP-1RA, empagliflozin was associated with similar risks of MI or stroke [HR: 0.99 (0.92, 1.07); RD: − 0.23 (− 1.25, 0.79)], and lower risks of HHF [HR: 0.69 (0.62, 0.77); RD: − 2.28 (− 2.98, − 1.59)], MACE [HR: 0.90 (0.82, 0.99); RD: − 2.54 (− 4.76, − 0.32)], cardiovascular mortality or HHF [HR: 0.77 (0.69, 0.86); RD: − 4.11 (− 5.95, − 2.29)], and ESKD [0.75 (0.60, 0.94); RD: − 6.77 (− 11.97, − 1.61)].”

Figure 3 was also cut off on the right side with some columns missing which has now been corrected (Fig. 3).

Fig. 3
figure 3

Subgroup analyses for primary outcomes by age and sex. CAPTION: On the relative scale, empagliflozin was associated with a lower risk of MI/stroke in patients 65 years or older, while it was not associated with MI/stroke in patients younger than 65 years. The HR estimates were consistent across other subgroups for all outcomes. For all outcomes, RD estimates were larger in older than in younger patients, while they did not differ by sex

Full size image

  1. Htoo PT, Tesfaye H, Schneeweiss S, Wexler DJ, Everett BM, Glynn RJ, Schmedt N, Koeneman L, Déruaz-Luyet A, Paik JM, Patorno E. Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study. Cardiovasc Diabetol. 2024;23(1):57. https://doi.org/10.1186/s12933-024-02150-0.

    Article CAS PubMed PubMed Central Google Scholar

Download references

Authors and Affiliations

  1. Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, 1620 Tremont Street, Suite 3030, Boston, MA, 02120, USA

    Phyo T. Htoo, Helen Tesfaye, Sebastian Schneeweiss, Robert J. Glynn, Julie M. Paik & Elisabetta Patorno

  2. Massachusetts General Hospital Diabetes Center, Harvard Medical School, Boston, USA

    Deborah J. Wexler

  3. Divisions of Cardiovascular and Preventive Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, 75 Francis Street, Boston, MA, USA

    Brendan M. Everett

  4. Global Epidemiology, Boehringer Ingelheim International GmbH (Germany) DE, Berlin, Germany

    Niklas Schmedt & Anouk Déruaz-Luyet

  5. Global Medical Affairs, Lilly Deutschland GmbH, Bad Homburg, Germany

    Lisette Koeneman

  6. Division of Renal (Kidney) Medicine, Brigham and Women’s Hospital, Boston, MA, USA

    Julie M. Paik

Authors
  1. Phyo T. HtooView author publications

    You can also search for this author in PubMed Google Scholar

  2. Helen TesfayeView author publications

    You can also search for this author in PubMed Google Scholar

  3. Sebastian SchneeweissView author publications

    You can also search for this author in PubMed Google Scholar

  4. Deborah J. WexlerView author publications

    You can also search for this author in PubMed Google Scholar

  5. Brendan M. EverettView author publications

    You can also search for this author in PubMed Google Scholar

  6. Robert J. GlynnView author publications

    You can also search for this author in PubMed Google Scholar

  7. Niklas SchmedtView author publications

    You can also search for this author in PubMed Google Scholar

  8. Lisette KoenemanView author publications

    You can also search for this author in PubMed Google Scholar

  9. Anouk Déruaz-LuyetView author publications

    You can also search for this author in PubMed Google Scholar

  10. Julie M. PaikView author publications

    You can also search for this author in PubMed Google Scholar

  11. Elisabetta PatornoView author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elisabetta Patorno.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Htoo, P.T., Tesfaye, H., Schneeweiss, S. et al. Correction: Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study. Cardiovasc Diabetol 23, 103 (2024). https://doi.org/10.1186/s12933-024-02190-6

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s12933-024-02190-6

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative



中文翻译：
更正：恩格列净与胰高血糖素样肽 1 受体激动剂的心肾功效：EMPRISE 研究的最终结果

更正：心血管糖尿病学（2024）23:57 https://doi.org/10.1186/s12933-024-02150-0

原始文章 [1] 发表后，作者注意到摘要中心力衰竭 (HHF) 住院结果的风险比 (HR) 存在错误。手稿其他部分和表格中的数字是正确的。

在摘要部分，正确的句子应为“与 GLP-1RA 相比，恩格列净与 MI 或中风的相似风险相关[HR: 0.99 (0.92, 1.07)；RD：− 0.23 (− 1.25, 0.79)]，HHF 风险较低[HR：0.69 (0.62, 0.77)；RD：- 2.28（- 2.98，- 1.59）]，MACE [HR：0.90（0.82，0.99）；RD：− 2.54 (− 4.76，− 0.32)]，心血管死亡率或 HHF [HR：0.77 (0.69，0.86)；RD：− 4.11 (− 5.95，− 2.29)]，ESKD [0.75 (0.60，0.94)；RD：- 6.77 (- 11.97，- 1.61)]。”

图 3 的右侧也被截断，缺少一些列，现已更正（图 3）。

图3
图3

按年龄和性别对主要结局进行亚组分析。图片说明：在相对范围内，恩格列净与 65 岁或以上患者的 MI/中风风险较低相关，而与 65 岁以下患者的 MI/中风风险无关。对于所有结果，其他亚组的 HR 估计都是一致的。对于所有结果，老年患者的 RD 估计值大于年轻患者，但它们在性别上没有差异

全尺寸图像

  1. Htoo PT、Tesfaye H、Schneeweiss S、Wexler DJ、Everett BM、Glynn RJ、Schmedt N、Koeneman L、Déruaz-Luyet A、Paik JM、Patorno E。恩格列净与胰高血糖素样肽 1 受体激动剂的心肾功效： EMPRISE 研究的最终结果。心血管糖尿病。2024；23(1):57。https://doi.org/10.1186/s12933-024-02150-0。

    文章 CAS PubMed PubMed Central Google Scholar

下载参考资料

作者和单位

  1. 布莱根妇女医院和哈佛医学院医学部药物流行病学和药物经济学部，1620 Tremont Street, Suite 3030, Boston, MA, 02120, USA

    Phyo T. Htoo、Helen Tesfaye、Sebastian Schneeweiss、Robert J. Glynn、Julie M. Paik 和 Elisabetta Patorno

  2. 马萨诸塞州总医院糖尿病中心，哈佛医学院，波士顿，美国

    黛博拉·韦克斯勒

  3. 哈佛医学院布莱根妇女医院医学系心血管和预防医学科，75 Francis Street，波士顿，马萨诸塞州，美国

    布伦丹·M·埃弗里特

  4. 全球流行病学，勃林格殷格翰国际有限公司（德国）DE，柏林，德国

    尼克拉斯·施迈特 & 阿努克·德鲁阿兹-吕耶

  5. 全球医疗事务部，礼来德国有限公司，德国巴特洪堡

    莉赛特·科尼曼

  6. 美国马萨诸塞州波士顿布莱根妇女医院肾脏科

    朱莉·M·白

作者
  1. Phyo T. Htoo查看作者出版物

    您也可以在PubMed Google Scholar中搜索该作者 

  2. Helen Tesfaye查看作者出版物

    您也可以在PubMed Google Scholar中搜索该作者 

  3. Sebastian Schneeweiss查看作者出版物

    您也可以在PubMed Google Scholar中搜索该作者 

  4. Deborah J. Wexler查看作者出版物

    您也可以在PubMed Google Scholar中搜索该作者 

  5. Brendan M. Everett查看作者出版物

    您也可以在PubMed Google Scholar中搜索该作者 

  6. 罗伯特·J·格林查看作者出版物

    您也可以在PubMed Google Scholar中搜索该作者 

  7. Niklas Schmedt查看作者出版物

    您也可以在PubMed Google Scholar中搜索该作者 

  8. Lisette Koeneman查看作者出版物

    您也可以在PubMed Google Scholar中搜索该作者 

  9. Anouk Déruaz-Luyet查看作者出版物

    您也可以在PubMed Google Scholar中搜索该作者 

  10. Julie M. Paik查看作者出版物

    您也可以在PubMed Google Scholar中搜索该作者 

  11. Elisabetta Patorno查看作者出版物

    您也可以在PubMed Google Scholar中搜索该作者 

通讯作者

通讯作者：伊丽莎白·帕托诺。

出版商备注

施普林格·自然对于已出版的地图和机构隶属关系中的管辖权主张保持中立。

开放获取本文根据知识共享署名 4.0 国际许可证获得许可，该许可证允许以任何媒介或格式使用、共享、改编、分发和复制，只要您对原作者和来源给予适当的认可，提供知识共享许可的链接，并指出是否进行了更改。本文中的图像或其他第三方材料包含在文章的知识共享许可中，除非材料的出处中另有说明。如果文章的知识共享许可中未包含材料，并且您的预期用途不受法律法规允许或超出了允许的用途，则您需要直接获得版权所有者的许可。要查看此许可证的副本，请访问 http://creativecommons.org/licenses/by/4.0/。知识共享公共领域奉献豁免 (http://creativecommons.org/publicdomain/zero/1.0/) 适用于本文中提供的数据，除非数据的信用额度中另有说明。

转载和许可

检查更新。 通过 CrossMark 验证货币和真实性

引用这篇文章

Htoo, PT、Tesfaye, H.、Schneeweiss, S.等人。更正：恩格列净与胰高血糖素样肽 1 受体激动剂的心肾功效：EMPRISE 研究的最后一年结果。心血管糖尿病 23 , 103 (2024)。https://doi.org/10.1186/s12933-024-02190-6

下载引文

  • 发表：

  • DOI ：https://doi.org/10.1186/s12933-024-02190-6

分享此文章

您与之分享以下链接的任何人都可以阅读此内容：

抱歉，本文目前没有可共享的链接。

由 Springer Nature SharedIt 内容共享计划提供
更新日期：2024-03-19
  点击分享   查看原文
点击收藏
公开下载
阅读更多本刊最新论文 本刊介绍/投稿指南
down
wechat
bug